Work

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.2004.2004

Authors: Vaishali Sanchorawala, Antje Hoering, David C Seldin, Kathleen T Finn, Salli A Fennessey, Bassam I Mattar, Hana F Safah, Leona Holmberg, Robert M. Dean, Robert Z. Orlowski, Bart Barlogie

Institutions: Boston University, Cancer Research And Biostatistics, Cancer Center of Kansas, Tulane University, University of Washington, Fred Hutch Cancer Center, Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arkansas for Medical Sciences

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2551633428

FWCI: 0.388

Cites:

Cited by: 3

Related to: 10